ESMO WCGIC 2021 | Impact of timing of perioperative chemotherapy on OS in patients with CRC liver metastases

Firas Baidoun, MD, Cleveland Clinic, Cleveland, OH, discusses the findings of a propensity score matching of the National Cancer Database investigating the impact of the timing perioperative chemotherapy on survival outcomes among patients with colorectal liver metastases. In this analysis, it was found that patients with colorectal cancer and isolated liver metastases who were treated with neoadjuvant chemotherapy had a statistically significant improvement in overall survival (OS) when compared to patients who were treated with adjuvant chemotherapy. This interview took place at the ESMO World Congress on Gastrointestinal Cancer 2021.